These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26921089)

  • 1. In Vitro and In Vivo Evaluation of Targeted Sunitinib-Loaded Polymer Microbubbles Against Proliferation of Renal Cell Carcinoma.
    Hu J; Zong Y; Li J; Zhou X; Zhang J; Zhu T; Jiao M; Su H; Bo B
    J Ultrasound Med; 2016 Mar; 35(3):589-97. PubMed ID: 26921089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hispidulin potentiates the antitumor effect of sunitinib against human renal cell carcinoma in laboratory models.
    Gao H; Jiang Q; Han Y; Peng J; Wang C
    Cell Biochem Biophys; 2015 Mar; 71(2):757-64. PubMed ID: 25260394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting renal cell carcinoma with gambogic acid in combination with sunitinib in vitro and in vivo.
    Jiang XL; Zhang Y; Luo CL; Wu XH
    Asian Pac J Cancer Prev; 2012; 13(12):6463-8. PubMed ID: 23464475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
    Sakai I; Miyake H; Fujisawa M
    BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
    Maita S; Yuasa T; Tsuchiya N; Mitobe Y; Narita S; Horikawa Y; Hatake K; Fukui I; Kimura S; Maekawa T; Habuchi T
    Int J Cancer; 2012 Feb; 130(3):677-84. PubMed ID: 21387300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual effect of ultrasound-targeted microbubble destruction in mediating recombinant adeno-associated virus delivery in renal cell carcinoma: transfection enhancement and tumor inhibition.
    Li F; Jin L; Wang H; Wei F; Bai M; Shi Q; Du L
    J Gene Med; 2014; 16(1-2):28-39. PubMed ID: 24464622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
    Miyazaki A; Miyake H; Fujisawa M
    Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma.
    Yu N; Fu S; Xu Z; Liu Y; Hao J; Zhang A; Wang B
    Int J Cancer; 2016 Jan; 138(2):451-62. PubMed ID: 26239999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.
    Han KS; Raven PA; Frees S; Gust K; Fazli L; Ettinger S; Hong SJ; Kollmannsberger C; Gleave ME; So AI
    Neoplasia; 2015 Nov; 17(11):805-16. PubMed ID: 26678908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
    Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC.
    Oosterwijk-Wakka JC; de Weijert MC; Franssen GM; Leenders WP; van der Laak JA; Boerman OC; Mulders PF; Oosterwijk E
    Neoplasia; 2015 Feb; 17(2):215-24. PubMed ID: 25748241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy.
    Jha BK; Dong B; Nguyen CT; Polyakova I; Silverman RH
    Mol Ther; 2013 Sep; 21(9):1749-57. PubMed ID: 23732991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney cancer: Power couple: reovirus meets sunitinib.
    Thoma C
    Nat Rev Urol; 2016 Aug; 13(8):436. PubMed ID: 27296650
    [No Abstract]   [Full Text] [Related]  

  • 15. A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.
    Maitani Y; Saito H; Seishi Y; Iwase Y; Yamauchi T; Higashiyama K; Sugino T
    J Drug Target; 2012 Dec; 20(10):873-82. PubMed ID: 23050928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma.
    Larkin J; Esser N; Calvo E; Tsuchihashi Z; Fiedler U; Graeser R; Kim D
    Anticancer Res; 2012 Jul; 32(7):2399-406. PubMed ID: 22753696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
    Lawson KA; Mostafa AA; Shi ZQ; Spurrell J; Chen W; Kawakami J; Gratton K; Thakur S; Morris DG
    Clin Cancer Res; 2016 Dec; 22(23):5839-5850. PubMed ID: 27220962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of High-Intensity Focused Ultrasound on Drug Release from Doxorubicin-Loaded PEGylated Liposomes and Therapeutic Effect in Colorectal Cancer Murine Models.
    Jeong HS; Hwang H; Oh PS; Kim EM; Lee TK; Kim M; Kim HS; Lim ST; Sohn MH; Jeong HJ
    Ultrasound Med Biol; 2016 Apr; 42(4):947-55. PubMed ID: 26795498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.
    Bousquet G; Varna M; Ferreira I; Wang L; Mongiat-Artus P; Leboeuf C; de Bazelaire C; Faivre S; Bertheau P; Raymond E; Germain S; Janin A
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1183-93. PubMed ID: 24061866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.